Federica Banterla

Dynamics of complement activation in aHUS and how to monitor eculizumab therapy

Marina Noris, Miriam Galbusera, Sara Gastoldi et al. · Blood · 2014 · 333 citations · Full text

Life Sciences, Immunology, Internal Medicine +13

Mutations in <i>FN1</i> cause glomerulopathy with fibronectin deposits

Federica Castelletti, Roberta Donadelli, Federica Banterla et al. · Proceedings of the National Academy of Sciences · 2008 · 155 citations · Full text

Medicine, Genetics, Molecular Genetics +17

In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura

Roberta Donadelli, Federica Banterla, Miriam Galbusera et al. · Thrombosis and Haemostasis · 2006 · 77 citations

Medicine, Genetics, Hematology +13

ADAMTS13 Predicts Renal and Cardiovascular Events in Type 2 Diabetic Patients and Response to Therapy

Erica Rurali, Marina Noris, Antonietta Chianca et al. · Diabetes · 2013 · 30 citations · Full text

Medicine, Molecular Medicine, Nephrology +15

ADAMTS13 Secretion and Residual Activity among Patients with Congenital Thrombotic Thrombocytopenic Purpura with and without Renal Impairment

Erica Rurali, Federica Banterla, Roberta Donadelli et al. · Clinical Journal of the American Society of Nephrology · 2015 · 17 citations · Full text

Medicine, Hematology, Pathology +12